Thor Medical ASA - Share Capital Increase in Relation to the Private Placement and the Retail Offering is Registered
10.9.2026 10:09:37 CEST | Thor Medical ASA | Total number of voting rights and capital
Oslo, Norway, 10 September 2026: Reference is made to stock exchange announcements by Thor Medical ASA (the "Company") on 3 September 2026 regarding the completion of a private placement of 60,260,000 new shares at a subscription price of NOK 4.80 per share, raising gross proceeds of approx. NOK 289.2 million (the "Private Placement"), and a retail offering of 2,240,000 new shares at a subscription price of NOK 4.80 per share, facilitated by Nordnet Bank AB, raising gross proceeds of approx. NOK 10.8 million (the "Retail Offering").
The Private Placement and the Retail Offering raised aggregate gross proceeds of NOK 300 million.
The share capital increases relating to the Private Placement and the Retail Offering are now registered with the Norwegian Register of Business Enterprises. The Company's share capital is after the registration NOK 84,500,364 divided into 422,501,820 shares. Each share has a nominal value of NOK 0.20 and represents one vote in the Company's general meeting.
DISCLOSURE REGULATION
This information is required to be disclosed under Section 5-12 of the Securities Trading Act.
CONTACTS
Mathias Nilsen Reierth, Head of Communications and Corporate Affairs, Thor Medical ASA, +47 988 05 724, mathias.reierth@thormedical.com - brede.ellingseter@thormedical.com
ABOUT THOR MEDICAL ASA
Thor Medical is a leading supplier of high-purity isotopes to the radiopharmaceutical industry. The Company's proprietary production platform combines advanced separation technology with industrial-scale manufacturing capacity to deliver a reliable, scalable and cost-efficient supply of alpha-emitting radioisotopes. Thor Medical supports radiopharmaceutical companies from early-stage development to commercialization, enabling scale-up of next-generation targeted cancer therapies. Thor Medical's product portfolio includes lead-212 (Pb-212) and its precursor isotopes thorium-228 (Th-228) and radium-224 (Ra-224). Based on naturally occurring thorium, Thor Medical's production process requires neither irradiation nor nuclear reactors, providing significant cost advantages while minimizing radioactive waste. Thor Medical is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange under the ticker symbol TRMED. For more information, visit https://www.thormedical.com/.
ATTACHMENTS
Download announcement as PDF.pdf - https://kommunikasjon.ntb.no/ir-files/17848634/19058987/17095/Download%20announc ement%20as%20PDF.pdf
More information: Access the news on Oslo Bors NewsWeb site